Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Ontology highlight
ABSTRACT: The currently available therapeutic options for patients with TP53-mutated acute myeloid leukemia (AML) are insufficient, as they translate to a median overall of only 6-9 months, and less than 10% of patients undergoing the most aggressive treatments, such as intensive induction therapy and allogeneic hematopoietic stem cell transplantation, will be cured. The lack of clear differences in outcomes with different treatments precludes the designation of a standard of care. Recently, there has been growing attention on this critical area of need by way of better understanding the biology of TP53 alterations and the disparities in outcomes among patients in this molecular subgroup, reflected in the development and testing of agents with novel mechanisms of action. Promising prec
SUBMITTER: Shallis RM
PROVIDER: S-EPMC9140008 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature
ACCESS DATA